NeuroSense Must Restore $1.00 Bid and $35M Market Value by September 29
NeuroSense Therapeutics received Nasdaq notices for failing to maintain its closing bid above $1.00 per share and a market value below $35 million for 30 consecutive business days through March 31, 2026. The company has until September 29, 2026 to restore a $1.00 bid and $35M market value for at least 10 consecutive business days to avoid delisting.
1. Non-Compliance Notifications
NeuroSense Therapeutics received two notification letters on April 2, 2026 indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) for minimum bid price and Listing Rule 5550(b)(2) for minimum market value of listed securities. The company's ordinary shares closed below $1.00 per share and its market value of listed securities fell under $35 million for 30 consecutive business days through March 31, 2026.
2. Compliance Requirements and Timeline
Under Nasdaq rules, NeuroSense has 180 calendar days—until September 29, 2026—to regain compliance by maintaining a closing bid price of at least $1.00 per share and a market value of $35 million or more for at least 10 consecutive business days. Failure to meet these thresholds within the compliance period could result in delisting of the company's ordinary shares and warrants from The Nasdaq Capital Market.
3. Company Response and Strategy
Management is actively evaluating potential actions to restore compliance, focusing on strategic, operational, and financing initiatives that support long-term shareholder value. The company continues to monitor daily closing prices and market capitalization while exploring measures aimed at meeting Nasdaq’s continued listing requirements.